Bacil Pharma Ltd.

View in App
20.28 +0.39 ▲2.0%

25 April 2024, 04:01:00 PM
Volume: 2,500

Company Profile

View details >>
Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.bacilpharma.com
Market Cap 11.94 Cr.
Enterprise Value(EV) 11.98 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) -0.16 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2023-12
Industry PE 41.74 Trailing Twelve Months Ending 2023-12
Book Value / Share 0.75 Trailing Twelve Months Ending 2023-12
Price to Book Value 26.95 Calculated using Price: 20.28
Dividend Yield 0.00 Period Ending 2023-03
No. of Shares Subscribed 0.59 Cr. 5,890,000 Shares
FaceValue 10
About Bacil Pharma Ltd.
Bacil Pharma was incorporated in the year 1987. Its plant is located at Lote-Parshuraram, an industrial area about 250 kilometer from Mumbai city.

Bacil Pharma Ltd. Delivery

View details >>
Delivered Qty
Traded Qty

Bacil Pharma Ltd. Performance

View details >>
1 Day
+1.96%
1 Week
+11.86%
1 Month
+46.96%
3 Month
+171.49%
6 Month
+130.98%
1 Year
+261.50%
2 Year
+317.28%
5 Year
+781.74%
10 Year
+1338.30%

Bacil Pharma Ltd. Fundamental Ratios

View details >>
9 years 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) -0.54 -1.23 -0.04 -101.39 -23.83 -31.16 -31.82 -575.48 -19.41
Return on Capital Employed (%) -0.48 -1.06 -0.03 -83.02 -16.18 -17.2 -15.05 -273.27 -8.44
Return on Assets (%) -0.48 -1.01 -0.03 -65.68 -7.53 -7.56 -6.06 -150.07 -9.37

Bacil Pharma Ltd. Balance Sheet

View details >>
Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 6 6 6 2 2 1 1 1 1 1
Non Curr. Liab. 0 0 0 0 0 0 0 0
Curr. Liab. 0 0 0 3 3 3 3 0 0 0
Minority Int.
Equity & Liab. 7 7 7 5 4 4 4 1 1 1
Non Curr. Assets 6 6 7 3 4 4 4 1 1 1
Curr. Assets 0 0 0 1 1 0 0 0 0 0
Misc. Exp. not W/O 1
Total Assets 7 7 7 5 4 4 4 1 1 1

Bacil Pharma Ltd. Profit and Loss

View details >>
Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales
Other Income 0 0 0 0 0 0 0 0 0 0
Total Income 0 0 0 0 0 0 0 0 0 0
Total Expenditure 0 0 0 0 0 0 0 -4 0 0
PBIDT 0 0 0 0 0 0 -4 0 0
Interest 0 0
Depreciation 0 0 0
Taxation
Exceptional Items -4
PAT 0 0 -4 0 0 0 -4 0 0
Adjusted EPS 0 0 -6 -1 -1 0 -7 0 0

Bacil Pharma Ltd. Cash Flow

View details >>
Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 0 0 0 1 0 0 0 -4 0
Cash Fr. Inv. 0 0 0 -1 0 0 1 4 0
Cash Fr. Finan. 0 0 0 0 0
Net Change 0 0 0 0 0 0 0 0 0 0
Cash & Cash Eqvt 0 0 0 0 0 0 0 0 0 0

Bacil Pharma Ltd. Shareholding Pattern

View details >>
9 Qtrs 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%) 2024-03 (%)
Promoter 42.67 42.67 42.67 42.67 42.67 42.67 42.67 42.67 42.67
Public 57.33 57.33 57.33 57.33 57.33 57.33 57.33 57.33 57.33
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
No. of Shareholders (in Lacs)

Bacil Pharma Ltd. Announcements

View details >>
Wed, 24 Apr 2024
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1 Name of Company BACIL PHARMA LTD.
2 CIN NO. L24200MH1987PLC043427
3 Report filed for FY 2023-2024
Details of the Current block (all figures in Rs crore):
4 2 - year block period (Specify financial years)* 2023-2024 2024-2025
5 Incremental borrowing done in FY (T)(a) 0.00
6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00
7 Actual borrowing done through debt securities in FY (T)(c) 0.00
8 Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d) 0
8Quantum of (d) which has been met from (c)(e)* 0
9 Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}* 0


Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):
2 - year Block period (Specify financial years)NA
Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#0.00



Name of the Company Secretary :-Bhavana Tak
Designation :-Company Secretary and Compliance officer
Name of the Chief Financial Officer :- Jayesh Patil
Designation : -CFO

Date: 24/04/2024
Wed, 24 Apr 2024
Compliance Certificate Under Reg 7(3)
Compliance Certificate under Reg 7(3)
Wed, 24 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1Name of CompanyBACIL PHARMA LTD.
2CIN NO.L24200MH1987PLC043427
3 Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) 0.00
4Highest Credit Rating during the previous FY NA
4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable
5Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the frameworkBSE


We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No



Name of the Company Secretary: Bhavana Tak
Designation: Company secretary and compliance officer
EmailId: bacilpha@yahoo.com
Name of the Chief Financial Officer: Jayesh Patil
Designation: CFO
EmailId: bacilpha@yahoo.com

Date: 24/04/2024

Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

Bacil Pharma Ltd. Technical Scans

View details >>
Thu, 25 Apr 2024
Higher Delivery Quantity Higher Delivery Quantity
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity
Close Crossing 52 Week High Close Crossing 52 Week High
Opening at High Opening at High

Bacil Pharma Ltd. Related Stocks

View details >>
  • SALES
Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 364,830.88 1,520.15 +2.3%
Cipla Ltd. 113,471.29 1,406.20 +0.6%
Dr. Reddy's Laboratories Ltd. 103,713.42 6,218.75 +4.5%
Divi's Laboratories Ltd. 101,959.84 3,843.80 +0.8%
Zydus Lifesciences Ltd. 95,944.41 951.25 +1.9%
Mankind Pharma Ltd. 95,926.91 2,398.55 +0.0%
Apollo Hospitals Enterprise Ltd. 91,425.47 6,384.10 +1.6%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 40.96 1,520.15 +2.3%
Cipla Ltd. Consolidated 2023-12 30.60 1,406.20 +0.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 19.84 6,218.75 +4.5%
Divi's Laboratories Ltd. Consolidated 2023-12 73.73 3,843.80 +0.8%
Zydus Lifesciences Ltd. Consolidated 2023-12 32.26 951.25 +1.9%
Mankind Pharma Ltd. Consolidated 2023-12 55.54 2,398.55 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 115.83 6,384.10 +1.6%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 5.85 1,520.15 +2.3%
Cipla Ltd. Consolidated 2023-12 4.38 1,406.20 +0.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.86 6,218.75 +4.5%
Divi's Laboratories Ltd. Consolidated 2023-12 7.82 3,843.80 +0.8%
Zydus Lifesciences Ltd. Consolidated 2023-12 5.09 951.25 +1.9%
Mankind Pharma Ltd. Consolidated 2023-12 10.80 2,398.55 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 13.54 6,384.10 +1.6%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,520.15 +2.3%
Cipla Ltd. Consolidated 2023-03 0.02 1,406.20 +0.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,218.75 +4.5%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,843.80 +0.8%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 951.25 +1.9%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 2,398.55 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 6,384.10 +1.6%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,520.15 +2.3%
Cipla Ltd. Consolidated 2023-03 12.85 1,406.20 +0.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,218.75 +4.5%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,843.80 +0.8%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 951.25 +1.9%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,398.55 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,384.10 +1.6%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,520.15 +2.3%
Cipla Ltd. Consolidated 2023-03 12.85 1,406.20 +0.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,218.75 +4.5%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,843.80 +0.8%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 951.25 +1.9%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,398.55 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,384.10 +1.6%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,520.15 +2.3%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,406.20 +0.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,218.75 +4.5%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,843.80 +0.8%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 951.25 +1.9%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 2,398.55 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 6,384.10 +1.6%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,520.15 +2.3%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,406.20 +0.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,218.75 +4.5%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,843.80 +0.8%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 951.25 +1.9%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 2,398.55 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 6,384.10 +1.6%

Bacil Pharma Ltd. FAQ's

What is Bacil Pharma share price?
Can I buy Bacil Pharma shares now?
What is the Market Cap of Bacil Pharma?
What are the key metrics to analyse Bacil Pharma?
What is the 52 Week High and Low of Bacil Pharma?
What is the trend of Bacil Pharma share price?